---
title: "European Commission Grants Approval of OGSIVEO®  ( nirogacestat )  for the Treatment of Adults with Desmoid Tumors"
description: "STAMFORD, Conn., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission ( EC ) granted"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253488882.md"
published_at: "2025-08-18T14:03:02.000Z"
---

# European Commission Grants Approval of OGSIVEO®  ( nirogacestat )  for the Treatment of Adults with Desmoid Tumors

> STAMFORD, Conn., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission ( EC ) granted marketing authorization for OGSIVEO® ( nirogacestat ) , an oral gamma secretase inhibitor, as ...

STAMFORD, Conn., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission ( EC ) granted marketing authorization for OGSIVEO® ( nirogacestat ) , an oral gamma secretase inhibitor, as ...

### Related Stocks

- [SWTX.US - SpringWorks Therapeutics](https://longbridge.com/en/quote/SWTX.US.md)

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.